SG43009A1 - Stem cell factor - Google Patents

Stem cell factor

Info

Publication number
SG43009A1
SG43009A1 SG1996002213A SG1996002213A SG43009A1 SG 43009 A1 SG43009 A1 SG 43009A1 SG 1996002213 A SG1996002213 A SG 1996002213A SG 1996002213 A SG1996002213 A SG 1996002213A SG 43009 A1 SG43009 A1 SG 43009A1
Authority
SG
Singapore
Prior art keywords
scf
dna sequence
stem cell
cell factor
biological activity
Prior art date
Application number
SG1996002213A
Other languages
English (en)
Inventor
Kristina M Zsebo
Sidney Vaughn Suggs
Robert A Bosselman
Francis Hall Martin
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1990/005548 external-priority patent/WO1991005795A1/en
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of SG43009A1 publication Critical patent/SG43009A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Hall/Mr Elements (AREA)
SG1996002213A 1989-10-16 1990-10-04 Stem cell factor SG43009A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US42238389A 1989-10-16 1989-10-16
US53719890A 1990-06-11 1990-06-11
US57361690A 1990-08-24 1990-08-24
PCT/US1990/005548 WO1991005795A1 (en) 1989-10-16 1990-09-28 Stem cell factor
US58970190A 1990-10-01 1990-10-01

Publications (1)

Publication Number Publication Date
SG43009A1 true SG43009A1 (en) 1997-10-17

Family

ID=27503703

Family Applications (2)

Application Number Title Priority Date Filing Date
SG1996002213A SG43009A1 (en) 1989-10-16 1990-10-04 Stem cell factor
SG1996001817A SG59931A1 (en) 1989-10-16 1990-10-04 Stem cell factor

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG1996001817A SG59931A1 (en) 1989-10-16 1990-10-04 Stem cell factor

Country Status (11)

Country Link
US (3) US6218148B1 (zh)
EP (4) EP0992579B1 (zh)
CN (2) CN1289526C (zh)
AT (2) ATE194651T1 (zh)
CZ (3) CZ286304B6 (zh)
DE (2) DE69034258D1 (zh)
DK (1) DK0423980T3 (zh)
GR (1) GR3034559T3 (zh)
HK (1) HK1010397A1 (zh)
SG (2) SG43009A1 (zh)
SK (2) SK281487B6 (zh)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759215B1 (en) * 1989-10-16 2004-07-06 Amgen Inc. Method of preparing human stem cell factor polypeptide
EP0536317A1 (en) * 1990-06-25 1993-04-14 Immunex Corporation Mast cell growth factor
US5767074A (en) * 1990-08-27 1998-06-16 Sloan-Kettering Institute For Cancer Research Compositions of soluble C-kit ligand and hematopoietic factors
US20030125519A1 (en) * 1990-08-27 2003-07-03 Peter Besmer Ligand for the c-kit receptor and methods of use thereof
US20050276784A1 (en) * 1990-08-27 2005-12-15 Solan-Kettering Institute For Cancer Research Ligand for the c-kit receptor and methods of use thereof
DE4224050A1 (de) * 1991-07-31 1993-02-04 Hoffmann La Roche Loesliche kit-liganden
US6001803A (en) * 1992-04-23 1999-12-14 Sloan-Kettering Institute For Cancer Research Composition of c-kit ligand, GM-CSF, and TNF-α and method of use
CA2133982C (en) * 1992-04-23 2008-02-12 Peter Besmer Ligand for the c-kit receptor and methods of use thereof
US6288030B1 (en) 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
US5525708A (en) * 1994-03-28 1996-06-11 Cytomed, Inc. Covalent dimer of kit ligand
DE69534324T2 (de) 1994-11-04 2006-01-05 Applied Research Systems Ars Holding N.V. Menschliche scf, eine spleissvariante davon,ihre pharmazeutische verwendung
US5824789A (en) * 1995-06-07 1998-10-20 Systemix, Inc. Human growth factors, nucleotide sequence encoding growth factors, and method of use thereof
US5731284A (en) * 1995-09-28 1998-03-24 Amgen Inc. Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product
US6184200B1 (en) 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
BR9610802A (pt) 1995-10-04 1999-07-13 Immunex Corp Método para melhoria da resposta imunológica método de preparo de células t de antígeno específico método para induzir tolerância de tecido de enxerto auxiliar de vacina meio de expansão e preparação de células dentríticas população de células dentríticas e respectivo método de preparo método para direcionar células-tronco hematopoiéticas ou células progenitoras a uma linhagem de células dentríticas
US5641749A (en) * 1995-11-29 1997-06-24 Amgen Inc. Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
US5641750A (en) * 1995-11-29 1997-06-24 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
US5741778A (en) * 1996-03-19 1998-04-21 Amgen Inc. Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product
US5885962A (en) * 1996-04-05 1999-03-23 Amgen Inc. Stem cell factor analog compositions and method
WO1998006422A1 (fr) 1996-08-13 1998-02-19 Fujisawa Pharmaceutical Co., Ltd. Agents de proliferation des cellules souches hematopoietiques
US6967092B1 (en) 1996-10-25 2005-11-22 Mc Kearn John P Multi-functional chimeric hematopoietic receptor agonists
US5969105A (en) * 1996-10-25 1999-10-19 Feng; Yiqing Stem cell factor receptor agonists
JPH10158188A (ja) * 1996-11-29 1998-06-16 Senju Pharmaceut Co Ltd 角膜治療用組成物
DE60044945D1 (de) * 1999-12-23 2010-10-21 Univ Geneve Auf scf peptid basiertes basolaterales sortiersignal und inhibitoren dafür
US7767197B2 (en) 2000-06-22 2010-08-03 Endo Pharmaceuticals Colorado LLC Delivery vehicle composition and methods for delivering antigens and other drugs
US6875441B2 (en) * 2000-06-26 2005-04-05 Rxkinetix, Inc. Composition for delivery of hematopoietic growth factor
JP2004529740A (ja) * 2001-06-15 2004-09-30 ジョーンズ ホプキンズ シンガポール ピーティーイー リミテッド 生体機能繊維
AU2002363322A1 (en) * 2001-10-26 2003-05-19 Large Scale Biology Corporation Endothelial cell derived hemotopoietic growth factor
EP1451332B1 (en) * 2001-11-27 2008-02-13 neXyte AB Production of eukaryotic proteins and nucleic acid molecules in c. elegans
WO2004071523A1 (en) * 2003-02-14 2004-08-26 Istituto Superiore Di Sanita Stem cell factor for preventing chemotherapy-induced depletion of blood cells
CN100345971C (zh) * 2003-07-14 2007-10-31 第二军医大学免疫学研究所 重组人干细胞因子的原核表达载体、工程菌及制备方法
AU2004299457B2 (en) 2003-12-12 2011-03-24 Government Of The United States Of America, As Represented By The Secretary Department Of Health And Human Services A human cytotoxic T-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of MUC-1
WO2006002344A1 (en) * 2004-06-23 2006-01-05 Epigenomics Ag Methods and nucleic acids for the detection of metastasis of colon cell proliferative disorders
EP1773981A1 (en) * 2004-07-12 2007-04-18 Sorin Group Italia S.R.L. Device and method for growing human cells
ATE544463T1 (de) 2004-11-05 2012-02-15 Univ Northwestern Verwendung von scf und g-scf bei der behandlung von hirnischämie und neurologischen störungen
MX2007015476A (es) 2005-06-14 2008-02-25 Amgen Inc Formulaciones de proteina autoamortiguadoras.
CA2915270C (en) * 2005-08-05 2017-07-11 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
US8404653B2 (en) * 2005-11-14 2013-03-26 Enterprise Partners Venture Capital Membrane bound stem cell factor therapy for ischemic heart
WO2007102814A2 (en) * 2006-03-07 2007-09-13 Regenetech, Inc. Recombinant mammalian molecules and method for production thereof
WO2007109583A2 (en) 2006-03-17 2007-09-27 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for prevention or treatment of neoplastic disease in a mammalian subject
EP3424507A1 (en) * 2006-03-24 2019-01-09 Children's Medical Center Corporation Method to modulate hematopoietic stem cell growth
WO2007137300A2 (en) 2006-05-23 2007-11-29 Bellicum Pharmaceuticals, Inc. Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
EP1872790A1 (en) 2006-06-26 2008-01-02 DeveloGen Aktiengesellschaft New formulation for increasing bioavailability of neurturin
MX2009004164A (es) 2006-10-20 2009-10-13 Childrens Medical Center Metodo para aumentar la regeneracion de tejido.
EP4335863A3 (en) 2007-07-09 2024-07-24 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
WO2009155041A2 (en) * 2008-05-28 2009-12-23 Children's Medical Center Corporation Method to modulate hematopoietic stem cell growth
EP2351599A4 (en) 2008-11-14 2013-05-08 Dnavec Corp METHOD FOR MANUFACTURING DENDRITIC CELLS
WO2010096264A2 (en) 2009-02-03 2010-08-26 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
US9051548B2 (en) 2009-02-03 2015-06-09 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
ES2808529T3 (es) 2011-01-10 2021-03-01 Univ Michigan Regents Inhibidor del factor de células madre
US20150018408A1 (en) 2013-07-10 2015-01-15 The Regents Of The University Of Michigan Therapeutic antibodies and uses thereof
PT2785834T (pt) 2011-12-02 2020-11-13 Fate Therapeutics Inc Composição de células estaminais melhorada
WO2013082241A2 (en) 2011-12-02 2013-06-06 Fate Therapeutics, Inc. Improved methods of treating ischemia
WO2014150602A1 (en) 2013-03-15 2014-09-25 Fate Therapeutics, Inc. Cell potency assay for therapeutic potential
US9889451B2 (en) 2013-08-16 2018-02-13 ADA-ES, Inc. Method to reduce mercury, acid gas, and particulate emissions
LT6161B (lt) 2013-09-27 2015-06-25 Uab Profarma Granuliocitų kolonijas stimuliuojančio faktoriaus sulieti baltymai su kitais augimo faktoriais, optimaliai su kamieninių ląstelių faktoriumi, ir jų gavimo būdas
JP6383216B2 (ja) * 2014-08-08 2018-08-29 シスメックス株式会社 血液分析方法、血液分析装置およびプログラム
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
CN105985424B (zh) * 2015-01-30 2019-08-23 苏州方舟生物医药有限公司 一种干细胞因子功能性肽段及其应用
CN105749252A (zh) * 2016-04-29 2016-07-13 南方医科大学 Il-9作为治疗血小板缺少症的药物的应用
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
CN108541660A (zh) * 2018-04-24 2018-09-18 上海动物园 动物饲养方法、动物饲养装置及其发酵床
JP2021534799A (ja) * 2018-08-27 2021-12-16 ノース カロライナ ステート ユニバーシティNorth Carolina State University 肥満細胞のアポトーシスを誘導するためにスプライススイッチングオリゴヌクレオチドを用いてＫｉｔを標的とする方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4695542A (en) * 1983-10-04 1987-09-22 Dnax Research Institute Of Molecular And Cellular Biology, Inc. cDNA clones coding for polypeptides exhibiting multi-lineage cellular growth factor activity
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS62223126A (ja) 1986-03-25 1987-10-01 Sankyo Co Ltd 血液幹細胞成長因子
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1

Also Published As

Publication number Publication date
CZ286303B6 (cs) 2000-03-15
US6207802B1 (en) 2001-03-27
CZ48897A3 (cs) 2000-01-12
SK500890A3 (en) 2001-04-09
DK0423980T3 (da) 2000-10-09
CN1306007A (zh) 2001-08-01
EP0992579B1 (en) 2008-08-06
DE69034258D1 (de) 2008-09-18
EP0423980A1 (en) 1991-04-24
SK281484B6 (sk) 2001-04-09
CZ286305B6 (cs) 2000-03-15
SK98199A3 (en) 2001-04-09
CZ286304B6 (cs) 2000-03-15
EP0676470A1 (en) 1995-10-11
DE69033584D1 (de) 2000-08-17
HK1010397A1 (en) 1999-06-17
ATE194651T1 (de) 2000-07-15
CN1075078C (zh) 2001-11-21
GR3034559T3 (en) 2001-01-31
CN1289526C (zh) 2006-12-13
EP0992579A1 (en) 2000-04-12
ATE403713T1 (de) 2008-08-15
DE69033584T2 (de) 2001-03-08
CZ49197A3 (cs) 2000-01-12
SK281487B6 (sk) 2001-04-09
SG59931A1 (en) 1999-02-22
US6207417B1 (en) 2001-03-27
CZ49097A3 (cs) 2000-01-12
EP1241258A2 (en) 2002-09-18
EP1241258A3 (en) 2003-12-10
EP0423980B1 (en) 2000-07-12
US6218148B1 (en) 2001-04-17
CN1051937A (zh) 1991-06-05

Similar Documents

Publication Publication Date Title
HK1010397A1 (en) Stem cell factor
ZA943464B (en) Vascular endothelial growth factor 2
HK1008400A1 (en) Genetic modification of endothelial cells
CA2095153A1 (en) Genetic modification of endothelial cells
WO1988002406A3 (en) Methods of regulating metabolic stability of proteins
EP0330451A3 (en) A cdna coding for human normal serum albumin a, and a process for production of the albumin
NO174351C (no) Fremgangsmåte for fremstilling av human insulinforlöper samt DNA-sekvens og vektor til anvendelse av fremgangsmåten
EP0859833A4 (en) RECOMBINANT HEPATITIS C VIRUS REPLICASE
DE68918867D1 (de) Mutanten des hiv-1 Hüllproteins mit fehlenden hypervariabelen domänen.
CA2038398A1 (en) Dna encoding a growth factor specific for epithelial cells
ZA943465B (en) Transforming growth factor alpha H1
EP0424416A4 (en) Acid-labile subunit (als) of insulin-like-growth factor (igf) binding protein complex
WO2000034474A3 (en) Growth factor homolog zvegf3
ES8506347A1 (es) Un metodo para producir un polipeptido de tipo il-2-".
MY104910A (en) New derivatives of human/bovine4 basic fibroblast growth factor.
Kurobe et al. Synthesis and secretion of an epidermal growth factor (EGF) by human fibroblast cells in culture
NO984491L (no) SCF-analogpreparater og fremgangsmÕte for fremstilling av disse
ES2004099A6 (es) Procedimiento de preparacion de polipeptidos biologicamente activos
ES8605296A1 (es) Procedimiento de producir factor viii-r humano
MXPA01011158A (es) Factor de crecimiento homologo zvegf4.
ZA892518B (en) Method for the in-vivo production and testing of proteins by recombinant gene expression in selected host-cells
IL91475A0 (en) Production of gonadotropin superagonists by recombinant dna methods and said super agonists produced thereby
ATE116366T1 (de) Verfahren zur herstellung eines menschlichen ''neutrophil chemotactic factor''-polypeptids.
HUP9800520A2 (hu) Génexpresszió emlős sejtekben
AU4664489A (en) Ancrod proteins, their production and use